Category: Capital Markets

Alliance Negotiates Equity Partnership for Licensed Cultivation Facility in City of Long Beach

July 27, 2017 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) is pleased to announce that the Company has entered into negotiations with a private company for an equity partnership for a licensed cultivation facility in the City of Long Beach. The partnership will be for a 100% ownership in a 6000 sq. ft. licensed medical marijuana cultivation building and a 50% or higher ownership of the cultivation business. The intention would then be to add a Manufacturing License which would add an additional valuable revenue stream to the business. This would provide full ownership of the building and two revenue streams while leaving the running of the day-to-day business to the private company team.  Alliance also expects to provide tissue cultured plantlets to the facility and potentially other facilities in California via an “in-house” lab arrangement.  Alliance will be working with a long-time legal contact in California to begin working through the various rules and regulations with regard to foreign ownership of a US cannabis operation. Dennis Petke, Alliance Growers’ President and CEO, commented on the proposed partnership. “We are very excited to have been presented this tremendous opportunity in the heart of the marijuana-friendly state of California, in a location with the stature of The City of Long Beach. The market is making tremendous inroads into the...

Read More

New Health Canada Regulations Allow for Substantial Increase in MYM Vault Size

Vancouver, B.C., July 27, 2017 – MYM Nutraceuticals Inc., (CSE: MYM) (the “Company” or “MYM”) is extremely pleased to announce that Health Canada has introduced new regula-tions that will allow for a substantial increase in production at the Laval location vault size. The new regulations will increase the authorized capacity of the vault size from 320kg to 1000kg of dried cannabis. At full capacity, the increase in vault size represents an additional $3,400,000 in gross revenue. The new regulations enable MYM to manage the production of cannabis products based on the capacity and security of the vault. Secondly, low-value cannabis waste products will not be included in the maximum authorized storage capacity. This will create additional storage space in the secure vault for finished cannabis products. Under the new regulations, MYM will no longer have to wait for Health Canada to conduct a pre-license inspection to begin cultivation. MYM will now be required to demonstrate that the location is in good working order. Health Canada will follow up with inspections during the cultivation of cannabis. About MYM MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. To ensure a strong presence and growth potential within the industry, MYM is actively looking to the acquire complementary businesses and assets in the technology, nutraceuticals and...

Read More

Golden Leaf CEO William Simpson Issues Letter to Shareholders

TORONTO, ON–(Marketwired – July 27, 2017) – Golden Leaf Holdings Ltd. (“GLH” or the “Company”) (CSE: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, is issuing the letter below to shareholders. To Our Valued Shareholders: I want to take a moment to (re)introduce myself and give an update on the status of Golden Leaf Holdings. Last week the board of GLH made the decision to refocus our company and strengthen our management team by appointing me as the Chief Executive Officer. As many of you may know, I have been a hands-on manager and entrepreneur in the Cannabis industry for more than 15 years. As the founder and CEO of Chalice Farms, I have had a hand in literally every step across the Cannabis supply chain; from growing and processing the plant, to retail store design and management. There are few leaders in our industry who have my depth and breadth of experience. As the new CEO of Golden Leaf, I am pleased to provide an update on the recent progress that our company has made towards achieving its corporate objectives. While I am less than one week on the job as CEO, I have been intimately involved in the day-to-day operations of Chalice Farms, a subsidiary of GHL, and as such have a strong handle on our business. As I get deeper into...

Read More

Medical Marijuana, Inc. Subsidiary HempMedsĀ® Mexico Discusses Therapeutic Benefits of Cannabis During Annual International League Against Epilepsy Meeting

Renowned Mexican Neurologist Presents on Effects of Real Scientific Hemp Oil-X™ (RSHO-X™) in Treating Children with Severe Epilepsy SAN DIEGO, July 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Mexico participated in the LX Annual Meeting and National Congress of the Mexican Chapter of the International League Against Epilepsy, which took place in Tijuana, Mexico from July 26th to 29th. HempMeds® Mexico provided information about cannabinoid products for the treatment of neurodegenerative conditions, such as epilepsy, as well as the results obtained by Mexican doctors using the first cannabis based treatment approved in Mexico that is the Company’s Real Scientific Hemp Oil-X™ (RSHO-X™). Mexican pediatric neurologist Dr. Saul Garza Morales presented information from a study involving 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy that typically develops before the age of four. Of those 39 patients, which took up to 5-7mg CBD/kg progressive doses of RSHO-X™ 5000MG, 84% experienced reduction in motor seizures; 53% reported better than a 75% reduction in seizures; and 17% reported a complete elimination of all seizures over a 4-month period, with zero reported side effects. “This was an incredible opportunity to meet with other doctors and discuss the latest research in the cannabinoid space,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “It was wonderful to see presentations made regarding the Endogenous Cannabinoid System and view some of the emerging...

Read More

Cara Therapeutics to Announce Second Quarter 2017 Financial Results on August 3, 2017

STAMFORD, Conn., July 27, 2017 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, August 3, 2017, at 4:30 p.m. ET to report second quarter 2017 financial results and provide a corporate update. To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 57769313. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website beginning approximately two hours after the call. About Cara Therapeutics Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pruritus and pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations 212-362-1200 michael@sternir.com MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 astarr@6degreespr.com Source:...

Read More